Rhythm Pharmaceuticals, Inc. (RYTM)

NASDAQ

$112.52

-$1.04 (0.92%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$111.56$116.34

Open $112.42

52 Week Range

$45.91$122.20

Previous Close $113.56

Market Cap7.51B

Volume1.05M

Avg Volume701.84K

P/E (TTM)-37.65

EPS (TTM)$-2.99

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Rhythm Pharmaceuticals, Inc.

DEC112025

Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

Source: GlobeNewsWire•5 days ago

-- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy -- -- Promising results supportive of Phase 3, registrational trial ...

DEC102025

Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

Source: GlobeNewsWire•5 days ago

BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it...

NOV102025

Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025

Source: GlobeNewsWire•36 days ago

– Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic obesity on concomitant treatment with GLP-1 therapy – – Analysis of data from Phase 3 TRANSCEND trial show clinically meani...

NOV72025

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

Source: GlobeNewsWire•39 days ago

-- FDA sets updated PDUFA goal date of March 20, 2026 – -- Company to hold conference today at 8:00 a.m. -- BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company fo...

NOV52025

Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program

Source: GlobeNewsWire•40 days ago

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it...

NOV42025

Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update

Source: GlobeNewsWire•42 days ago

-- Third quarter 2025 net product revenue from global sales of IMCIVREE ® (setmelanotide) of $51.3 million -- -- December 20, 2025 PDUFA goal date set for sNDA for setmelanotide in acquired hypothalamic obesity -- -- Company is on track to report pr...

OCT212025

Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Source: GlobeNewsWire•55 days ago

BOSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it...